New shot could tame birch pollen allergies, early trial hopes
NCT ID NCT07254871
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether an injection called DM-101PX can reduce nasal symptoms caused by birch pollen allergy. About 100 adults with birch pollen allergic rhinitis or rhinoconjunctivitis will receive either the drug or a placebo. The main goal is to see if the treatment lowers symptom scores during a nasal allergen challenge.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DM-101PX (a biologic injection)
- What this could lead to
- If it works, this could lead to a new treatment that eases nasal allergy symptoms during birch pollen season.
- What could go wrong
- This is an early Phase 2 trial with only 100 people, so results may not hold up in larger studies. The treatment is still experimental and may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIRCH POLLEN ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cliantha Research
Mississauga, Ontario, ON L4W 1A4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.